With fewer Part D plans and a $2,000 out-of-pocket cap, beneficiaries must rethink their Medicare drug coverage for 2025.
Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare ...
The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest ...
15h
The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and ...
The U.S. pharmaceutical industry is attempting to delay the timeline for Medicare's drug price negotiations following the ...
We need leaders to level with the American people about the challenges ahead — challenges Joe Biden understands well.
A record-low number of Medicare Part D plans could cause greater Medicare Advantage enrollment, which may not be a good thing ...
In one of the Biden administration’s final health policy pushes, the White House unveiled a proposal to ensure Medicare and Medicaid coverage for obesity drugs.
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to increase oversight of the Medicare Advantage and ...
The proposal would let patients get Wegovy, Ozempic and related drugs for obesity, which Medicare and Medicaid does not cover ...
Weight loss drugs like Wegovy, Zepbound and Ozempic would be covered by Medicare and Medicaid under a Biden administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback